4//SEC Filing
THREE ARCH ASSOCIATES IV LP 4
Accession 0000899243-18-013837
CIK 0001427925other
Filed
May 22, 8:00 PM ET
Accepted
May 23, 6:00 PM ET
Size
23.2 KB
Accession
0000899243-18-013837
Insider Transaction Report
Form 4
JAEGER WILFRED E
10% Owner
Transactions
- Other
Common Stock
2018-05-21−3,347,357→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−5,713,569→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−179,962→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−126,153→ 0 total(indirect: See Footnote)
THREE ARCH PARTNERS III LP
10% Owner
Transactions
- Other
Common Stock
2018-05-21−179,962→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−126,153→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−3,347,357→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−5,713,569→ 0 total(indirect: See Footnote)
THREE ARCH PARTNERS IV LP
10% Owner
Transactions
- Other
Common Stock
2018-05-21−179,962→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−3,347,357→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−5,713,569→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−126,153→ 0 total(indirect: See Footnote)
THREE ARCH ASSOCIATES IV LP
10% Owner
Transactions
- Other
Common Stock
2018-05-21−126,153→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−179,962→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−3,347,357→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−5,713,569→ 0 total(indirect: See Footnote)
WAN MARK A
Director
Transactions
- Other
Common Stock
2018-05-21−3,347,357→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−179,962→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−5,713,569→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−126,153→ 0 total(indirect: See Footnote)
THREE ARCH ASSOCIATES III LP
10% Owner
Transactions
- Other
Common Stock
2018-05-21−3,347,357→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−179,962→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−5,713,569→ 0 total(indirect: See Footnote) - Other
Common Stock
2018-05-21−126,153→ 0 total(indirect: See Footnote)
Footnotes (7)
- [F1]The shares are owned directly by Three Arch Partners III, L.P. ("TAP III"). Three Arch Management III, L.L.C. ("TAM III"), the general partner of TAP III, had sole voting and dispositive power with respect to the securities held by TAP III. Mark A. Wan and Wilfred Jaeger, the managing members of TAM III, shared the voting and dispositive power with respect to the shares held by TAP III. Such persons and entities disclaim beneficial ownership of the shares held by TAP III except to the extent of any pecuniary interest therein. See Explanation of Responses #5 for more information.
- [F2]The shares are owned directly by Three Arch Associates III, L.P. ("TAA III"). TAM III, the general partner of TAA III, had sole voting and dispositive power with respect to the securities held by TAA III. Mark A. Wan and Wilfred Jaeger, the managing members of TAM III, shared the voting and dispositive power with respect to the shares held by TAA III. Such persons and entities disclaim beneficial ownership of the shares held by TAA III except to the extent of any pecuniary interest therein. See Explanation of Responses #5 for more information.
- [F3]The shares are owned directly by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, had sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred Jaeger, the managing members of TAM IV, shared the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. See Explanation of Responses #5 for more information.
- [F4]The shares are owned directly by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, had sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred Jaeger, the managing members of TAM IV, shared the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. See Explanation of Responses #5 for more information.
- [F5]On May 21, 2018, the TAP III, TAP IV, TAA III and TAA IV (the "Affiliated Entities") and certain other affiliates of the Affiliated Entities and Leerink Revelation Healthcare Fund I, L.P., Industry Ventures Secondary VIII, L.P. and Kline Hill Partners Fund II LP (the "Purchasers") entered into a purchase agreement (the "Purchase Agreement") pursuant to which the Affiliated Entities agreed to a sale to the Purchasers (the "Portfolio Sale") of a portfolio of assets held by the Affiliated Entities consisting of the securities of private and public companies, including the 9,367,041 shares of Common Stock (the "AcelRx Shares") of AcelRx Pharmaceuticals, Inc. (the "Issuer") and other investment interests. The transfer of the AcelRx Shares and the securities of another portfolio asset (such securities together with the AcelRx Shares, the "Initial Closing Securities") was consummated at an initial closing on May 21, 2018 to the Purchasers.
- [F6](Continued From Footenote 5) The Portfolio Sale was undertaken for portfolio management purposes in connection with the imminent expiration of the terms of the Affiliated Entities under their respective governing agreements, as the Affiliated Entities were initially formed between 1999 and 2004 with initially contemplated terms of ten years. The Portfolio Sale was undertaken as a result of the imminent dissolution of the Affiliated Entities due to the upcoming expiration of the terms under the governing agreements. The Portfolio Sale is not being undertaken as a result of an adverse change in the Affiliated Entities' views on the prospects of the Issuer, or its businesses, management or directors. Wan, a director of the Issuer and affiliate of the Affiliated Entities, will continue serving as a member of the Issuer's Board of Directors after the Portfolio Sale.
- [F7](Continued From Footenote 6) The aggregate purchase price to be paid by the Purchasers in the Portfolio Sale is $30 million in up front consideration, plus a residual amount calculated based on, among other things, the trading price of the AcelRx Shares and certain other securities as of the end of calendar year 2018, up to a maximum aggregate amount of $12.5 million in additional consideration (the "Residual Consideration"). The Initial Closing Securities sold by the Affiliated Entities in the Portfolio Sale were priced on an aggregate basis, for total consideration in the range of $25 million to $37.5 million, depending upon the amount of Residual Consideration eventually paid. Because the Initial Closing Securities sold by the Affiliated Entities in the Portfolio Sale were price on an aggregate basis, a price per share was not separately determined for the AcelRx Shares.
Documents
Issuer
ACELRX PHARMACEUTICALS INC
CIK 0001427925
Entity typeother
Related Parties
1- filerCIK 0001276986
Filing Metadata
- Form type
- 4
- Filed
- May 22, 8:00 PM ET
- Accepted
- May 23, 6:00 PM ET
- Size
- 23.2 KB